Position in GMED
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$67,158,500
+$14,556,097 QoQ
Shares Held
850,000
+39.2% QoQ
Ownership
0.633%
of shares outstanding
% of Portfolio
1.57%
of 13F equity value
Holder Rank
#36
of 597 holders
Holding Since
Dec 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GMED Over Time
Shares Held
Position Value (USD)
Position in Medical Devices
Healthcare · as of Jun 30, 2026Vestal Point Capital, LP holds $480,553,000 across 7 Medical Devices names. GMED ranks #4 (14.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABT |
Abbott Laboratories
|
1,400,000 | $127,036,000 | |
| 2 | ZBH |
Zimmer Biomet Holdings, Inc.
|
1,400,000 | $120,526,000 | |
| 3 | PODD |
Insulet Corp
|
670,000 | $102,007,500 | |
| 4 | GMED |
Globus Medical Inc
This page
|
850,000 | $67,158,500 | |
| 5 | GEHC |
GE HealthCare Technologies Inc.
|
450,000 | $28,804,500 | |
| 6 | BBNX |
Beta Bionics, Inc.
|
1,600,000 | $25,072,000 | |
| 7 | AVR |
Anteris Technologies Global Corp.
|
1,010,000 | $9,948,500 |
All Filings in GMED
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $67,158,500 | 850,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $52,602,403 | 610,520 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $111,320,250 | 1,275,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $71,587,500 | 1,250,000 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $29,510,000 | 500,000 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $14,640,000 | 200,000 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $26,880,750 | 325,000 | Shares | Sole | 2025-02-14 | |
| 2024-06-30 | $61,641,000 | 900,000 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $53,640,000 | 1,000,000 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $42,632,000 | 800,000 | Shares | Sole | 2024-02-13 | |
| No filing history on record for this holder in this stock. | ||||||